Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03847649
Title Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Toxicity
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

Advanced Solid Tumor

Therapies

Durvalumab

Durvalumab + Prednisone

Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.